Mersana Therapeutics logo

Mersana Therapeutics Share Price (NASDAQ: MRSN)

$7.87

0.12

(1.55%)

Live

Last updated on

Check the interactive Mersana Therapeutics Stock chart to analyse performance

Mersana Therapeutics stock performance

as on August 26, 2025 at 12:34 AM IST

  • Today's Low:$7.75
    Today's High:$7.87

    Day's Volatility :1.52%

  • 52 Weeks Low:$5.21
    52 Weeks High:$70.75

    52 Weeks Volatility :92.64%

Mersana Therapeutics Stock Returns

PeriodMersana Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-13.89%
6.0%
0.0%
6 Months
-44.3%
-7.2%
0.0%
1 Year
-80.98%
-11.1%
0.0%
3 Years
-95.92%
5.5%
-10.0%

Mersana Therapeutics Inc Key Stats

Check Mersana Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$7.75
Open
$8.065
Today's High
$8.03
Today's Low
$7.6
Market Capitalization
$38.7M
Today's Volume
$71.7K
52 Week High
$70.75
52 Week Low
$5.21
Revenue TTM
$34.8M
EBITDA
$-70.6M
Earnings Per Share (EPS)
$-14.79
Profit Margin
-212.94%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-505.14%

Stock Returns calculator for Mersana Therapeutics Stock including INR - Dollar returns

The Mersana Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Mersana Therapeutics investment value today

Current value as on today

₹23,648

Returns

₹76,352

(-76.35%)

Returns from Mersana Therapeutics Stock

₹80,687 (-80.69%)

Dollar Returns*

₹4,335 (+4.33%)

Indian investors sentiment towards Mersana Therapeutics Stock

-13%

Period: Jul 25, 2025 to Aug 24, 2025. Change in 30 Days versus previous period

Search interest for Mersana Therapeutics Stock from India on INDmoney has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Mersana Therapeutics Inc

  • Name

    Holdings %

  • Nextech Invest, Ltd.

    9.67%

  • Bain Capital Life Sciences Investors, LLC

    6.94%

  • Vanguard Group Inc

    6.71%

  • BlackRock Inc

    6.67%

  • Schonfeld Strategic Advisors LLC

    6.10%

  • AQR Capital Management LLC

    4.12%

Analyst Recommendation on Mersana Therapeutics Stock

Rating
Trend

Buy

    80%Buy

    20%Hold

    0%Sell

Based on 15 Wall street analysts offering stock ratings for Mersana Therapeutics(by analysts ranked 0 to 5 stars)

Mersana Therapeutics Share Price Target

What analysts predicted

Upside of 259.41%

Target:

$28.29

Current:

$7.87

Mersana Therapeutics share price target is $28.29, a slight Upside of 259.41% compared to current price of $7.87 as per analysts' prediction.

Mersana Therapeutics Stock Insights

  • Price Movement

    In the last 6 months, MRSN stock has moved down by -41.2%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.75M → 3.05M (in $), with an average increase of 9.9% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -11.50M → -24.29M (in $), with an average decrease of 31.5% per quarter
  • MRSN vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.7% return, outperforming this stock by 146.8%
  • MRSN vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.4% return, outperforming this stock by 208.5%
  • Price to Sales

    ForMRSN every $1 of sales, investors are willing to pay $1.1, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Mersana Therapeutics Inc Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$40.5M
↑ 9.88%
Net Income
$-69.2M
↓ 59.69%
Net Profit Margin
-170.86%
↑ 294.94%

Mersana Therapeutics Technicals Summary

Sell

Neutral

Buy

Mersana Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Mersana Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Mersana Therapeutics Inc logo
13.47%
-44.3%
-80.98%
-95.92%
-98.31%
Regeneron Pharmaceuticals, Inc. logo
5.52%
-17.35%
-50.85%
-1.12%
-3.68%
Beone Medicines Ltd logo
6.51%
21.35%
57.45%
73.21%
25.84%
Vertex Pharmaceuticals Incorporated logo
-14.26%
-17.97%
-18.13%
40.27%
45.64%
Alnylam Pharmaceuticals, Inc. logo
39.9%
82.53%
68.83%
115.41%
241.51%

About Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Organization
Mersana Therapeutics
Employees
102
CEO
Dr. Martin H. Huber M.D.
Industry
Health Technology

Key Management of Mersana Therapeutics Inc

NameTitle
Dr. Martin H. Huber M.D.
President, CEO & Director
Mr. Brian C. DeSchuytner
Senior VP, CFO & COO
Dr. Timothy B. Lowinger Ph.D.
Senior VP and Chief Science & Technology Officer
Ms. Alejandra Veronica Carvajal J.D.
Senior VP, Secretary & Chief Legal Officer
Dr. Mohan Bala Ph.D.
Senior VP & Chief Development Officer
Mr. Mikhail Papisov Ph.D.
Co-Founder
Mr. Ashish Mandelia
VP & Chief Accounting Officer
Mr. Jason Fredette
Senior Vice President of Investor Relations & Corporate Communications
Mr. Chuck Miller
Senior Vice President of Regulatory Affairs
Dr. Marc Damelin Ph.D.
Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.

Important FAQs about investing in MRSN Stock from India :

What is Mersana Therapeutics share price today?

Mersana Therapeutics share price today is $7.87 as on . Mersana Therapeutics share today touched a day high of $7.87 and a low of $7.75.

What is the 52 week high and 52 week low for Mersana Therapeutics share?

Mersana Therapeutics share touched a 52 week high of $70.75 and a 52 week low of $5.21. Mersana Therapeutics stock price today i.e. is trending at $7.87, lower by 88.88% versus the 52 week high.

How to invest in Mersana Therapeutics Stock (MRSN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Mersana Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mersana Therapeutics Shares that will get you 0.1906 shares as per Mersana Therapeutics share price of $7.87 per share as on August 26, 2025 at 12:34 AM IST.

What is the minimum amount required to buy Mersana Therapeutics Stock (MRSN) from India?

Indian investors can start investing in Mersana Therapeutics (MRSN) shares with as little as ₹87.537 or $1 (as of August 25, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.37 in Mersana Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 25, 2025). Based on Mersana Therapeutics share’s latest price of $7.87 as on August 26, 2025 at 12:34 AM IST, you will get 1.2706 shares of Mersana Therapeutics. Learn more about fractional shares .

What are the returns that Mersana Therapeutics has given to Indian investors in the last 5 years?

Mersana Therapeutics stock has given -98.31% share price returns and 18.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?